Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Kytopen and Aldevron Expedite Cell Therapy Manufacturing Through Their Collaborative CRISPR-mediated Cellular Engineering Workflow

Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.High transgene expression and improved safety profile of Aldveron's Nanoplasmid™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer…

Revolutionary Partnership Promises Faster, Higher-Yield CAR-T Cell Manufacturing Using CRISPR Technology

Novel combination of Nanoplasmid and Flowfect Tx platforms delivers superior T-cell engineering results. New manufacturing process ready for clinical use. Learn more.

Investigating the Impact of the Microbiome on CAR T-Cell Therapy Outcomes

Certain antibiotics may have a more significant impact on CAR T-cell efficacy and toxicity.